Oklahoma SB771 prohibits direct-to-consumer pharmaceutical advertising by companies, creating a felony offense.
Oklahoma SB771 aims to prohibit direct-to-consumer (DTC) pharmaceutical advertising by companies, aligning the state with global norms. The bill defines DTC advertising as any promotional communication targeting consumers through various media that markets prescription drugs. Exceptions include communications required by law, public health campaigns, clinical trial promotions, and patient assistance programs. Violators face felony charges, with penalties including fines up to $500,000, imprisonment up to five years, or both.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.